A Phase 3 interventional study of KVD900 150 mg and KVD900 300 mg in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Completed at 24 sites in 7 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..
Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2024, is one of 4 in phase 3, and was the 8th registered.
171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.
Browse Angioedemas, Hereditary studies →1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:
KalVista Pharmaceuticals, Ltd. · Sites in United States
Ages 12+
By country, each count listing its studies:
Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is below the median of 48 across 116 interventional studies indexed under Angioedemas, Hereditary.
Median enrollment 84 across the 9 interventional studies, 88 across the 1 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under KalVista Pharmaceuticals, Ltd., one of the names counted as Chiesi Farmaceutici S.p.A.. Under that name alone:
KalVista Pharmaceuticals, Ltd. is the lead sponsor of 15 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
1 of the studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07654829KalVista Pharmaceuticals, Ltd.Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) | 2027-11-29 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
KVD900-303 is an open-label, multicenter clinical trial in patients aged 2 to 11 years old with HAE Type I or II.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will take a single 150 mg dose of KVD900.
Drug: KVD900 150 mg
Patients will take a single 300 mg dose of KVD900.
Drug: KVD900 300 mg
Patients will take a single 600 mg dose of KVD900.
Drug: KVD900 600 mg
KVD900 Tablet 150 mg (2 x 75 mg)
KVD900 Tablet 300 mg (1 x 300 mg)
KVD900 Tablet 600 mg (2 x 300 mg)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event (AE) that met any of the following conditions: (1) began on or after the first dose of IMP, (2) began before the first dose of IMP and increased in severity on or after first dose, (3) was completely missing a start date and the stop date, (4) was completely missing a start date and the stop date was on or after the first dose of IMP. An on-treatment TEAE was defined as any TEAE occurring within 3 days of IMP administration. A treatment-related TEAE was an AE considered related to the IMP by the investigator. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event (based upon medical and scientific judgment).
Time frame: From first dose of IMP until the Final/Early Termination (ET) Visit, up to a maximum of 54 weeks.
Plasma Concentrations of Sebetralstat
During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. Pharmacokinetic (PK) samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial.
Time frame: At 0.5 hours (±5 min), 2 hours (±15 min), and 4 hours (±15 min) post-dose. PK assessments for sebetralstat 300 mg ED were conducted at the Enrollment Visit, and for 600 mg ED at the Dose Increase Visit (up to 12.6 months after Enrollment Visit).
Pediatric participants (aged 2 to 11 years) with hereditary angioedema (HAE) Type I or II were enrolled at trial sites in Canada, Germany, France, Israel, Italy, Japan, and the United States (US). Participants enrolled under protocol v1.0 to v3.3 received sebetralstat 300 mg equivalent dosing (ED). Following a US-specific protocol amendment, dose levels were increased; US-only participants who continued under protocol v3.4 had a Dose Increase Visit and received sebetralstat 600 mg ED thereafter.
| Milestone | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg |
|---|---|---|---|
| Started | 3 | 27 | 6 |
| Received sebetralstat 300 mg ed (protocol v1.0 - 3.3) | 3 | 27 | 6 |
| Received sebetralstat 600 mg ed (protocol v3.4; us only) | 0 | 6 | 1 |
| Completed | 3 | 25 | 3 |
| Not completed | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
A TEAE was defined as an adverse event (AE) that met any of the following conditions: (1) began on or after the first dose of IMP, (2) began before the first dose of IMP and increased in severity on or after first dose, (3) was completely missing a start date and the stop date, (4) was completely missing a start date and the stop date was on or after the first dose of IMP. An on-treatment TEAE was defined as any TEAE occurring within 3 days of IMP administration. A treatment-related TEAE was an AE considered related to the IMP by the investigator. A serious AE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required in-patient hospitalization or prolongation, resulted in significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event (based upon medical and scientific judgment).
| Participants | Sebetralstat 300 mg ED | Sebetralstat 600 mg ED |
|---|---|---|
| Any TEAE | 20 | 1 |
| Any treatment-related TEAE | 0 | 0 |
| Any on-treatment TEAE | 11 | 1 |
| Any serious TEAE | 0 | 0 |
During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. Pharmacokinetic (PK) samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial.
| ng/mL | Sebetralstat 300 mg ED | Sebetralstat 600 mg ED |
|---|---|---|
| 0.5 hours post-dose | 1786.00 ± 1263.690 | 4042.86 ± 1843.056 |
| 2 hours post-dose | 1145.59 ± 775.594 | 2761.33 ± 1090.667 |
| 4 hours post-dose | 601.05 ± 1103.278 | 953.57 ± 563.929 |
During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. PK samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial. A final population-based PK model of sebetralstat was utilized to obtain individual post hoc estimates of PK parameters. For participants with measurable plasma concentrations of sebetralstat, Cmax was predicted using individual post hoc PK parameter estimates.
| ng/mL | Sebetralstat 300 mg ED | Sebetralstat 600 mg ED |
|---|---|---|
| Maximum Concentration (Cmax) of Sebetralstat | 2010 ± 42.9 | 4690 ± 30.5 |
During the Enrollment Visit, participants were dosed with IMP (sebetralstat 300 mg ED) and monitored for tolerability. PK samples were collected via venous access or capillary collection (eg, finger prick) at specified timepoints. For participants enrolled under protocol v3.4 who received sebetralstat 600 mg ED, a second PK assessment was performed at the Dose Increase Visit. The Dose Increase Visit occurred as soon as possible after implementation of the protocol amendment and could occur at any time during the participant's participation in the trial. A final population-based PK model of sebetralstat was utilized to obtain individual post hoc estimates of PK parameters. For participants with measurable plasma concentrations of sebetralstat, AUC0-inf was predicted using individual post hoc PK parameter estimates.
| ng*h/mL | Sebetralstat 300 mg ED | Sebetralstat 600 mg ED |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of Sebetralstat | 5350 ± 53.1 | 11660 ± 29.8 |
Collected over For all-cause mortality reporting, from enrollment until the Final/ET Visit; up to a maximum of 76 weeks for overall duration of trial. For AE reporting, from first dose of IMP until the Final/ET Visit, up to a maximum of 54 weeks. All-cause mortality is reported for all participants enrolled in the trial. Serious and Other AEs are reported for all participants who received at least 1 dose of IMP.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sebetralstat 300 mg ED | 0/36 (0%) | 0/36 (0%) | 20/36 (55.6%) |
| Sebetralstat 600 mg ED | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Event | Sebetralstat 300 mg ED | Sebetralstat 600 mg ED |
|---|---|---|
| NauseaGastrointestinal disorders | 0/36 | 1/7 |
| ParaesthesiaNervous system disorders | 0/36 | 1/7 |
| NasopharyngitisInfections and infestations | 5/36 | 0/7 |
| Upper respiratory tract infectionInfections and infestations | 5/36 | 0/7 |
| Abdominal pain upperGastrointestinal disorders | 4/36 | 0/7 |
| VomitingGastrointestinal disorders | 4/36 | 0/7 |
| HeadacheNervous system disorders | 4/36 | 0/7 |
| Ear infectionInfections and infestations | 2/36 | 0/7 |
| Gastrointestinal infectionInfections and infestations | 2/36 | 0/7 |
| InfluenzaInfections and infestations | 2/36 | 0/7 |
The Safety Set (SAF) included all participants who received at least 1 dose of IMP.
| Age, Continuous(years) | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg | Total |
|---|---|---|---|---|
| Median | 5.0 (4 to 5) | 8.0 (6 to 11) | 9.5 (8 to 10) | 8.0 (4 to 11) |
| Age, Customized(Participants) | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg | Total |
|---|---|---|---|---|
| 2 - 5 years | 3 | 0 | 0 | 3 |
| 6 - 11 years | 0 | 27 | 6 | 33 |
| Sex: Female, Male(Participants) | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg | Total |
|---|---|---|---|---|
| Female | 2 | 13 | 3 | 18 |
| Male | 1 | 14 | 3 | 18 |
| Ethnicity (NIH/OMB)(Participants) | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 3 | 21 | 5 | 29 |
| Unknown or Not Reported | 0 | 5 | 1 | 6 |
| Race(Participants) | Weight Group ≥9.5 to <20 kg | Weight Group ≥20 to ≤45 kg | Weight Group ≥45 kg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 1 | 1 | 2 |
| Black | 0 | 1 | 0 | 1 |
| Native Hawaiian or Pacific islander | 0 | 0 | 0 | 0 |
| White | 3 | 20 | 3 | 26 |
| Other | 0 | 1 | 0 | 1 |
| Not Reported | 0 | 4 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Data will not be shared until all global regulatory filings are complete.
Ran from Aug 2024 to primary completion in Jan 2026, 17 months.
Results were first posted in Aug 2026, 6 months after primary completion.
Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 17 months is below that.
Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sebetralstat
KalVista Pharmaceuticals, Ltd. →